Charles River Laboratories updated its 2026 outlook to reflect planned divestitures expected to close in the second quarter of 2026. Reported revenue is now forecast to decline 3.5% to 5.0% in 2026, compared with its prior view of at least flat to up 1.5%, as the divestitures are expected to reduce reported revenue by slightly more than $200 million and trim organic growth by more than 50 basis points. Despite the lower revenue base, the company raised its non-GAAP EPS range to $10.80 to $11.30 from $10.70 to $11.20, citing at least 100 basis points of incremental non-GAAP operating margin improvement and about $0.10 of partial-year EPS accretion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602250700BIZWIRE_USPR_____20260224_BW712091) on February 25, 2026, and is solely responsible for the information contained therein.